We focus on delivering solutions to patients and healthcare professionals via medicines and services for central nervous system disorders with a strong emphasis on multiple sclerosis, and other neurodegenerative disorders.
We concentrate on supporting the NHS in managing long-term conditions like multiple sclerosis and Parkinson's disease. Our aim is to work in partnership to develop joined-up care through Joint Working projects, to improve patient outcomes and enhance patient experience, and also to offer value for money. That might be through medicines optimisation, quality improvement, pathway redesign or improvement, innovation or identifying cost efficiencies.
Within Teva’s CNS medicines we have Copaxone® (glatiramer acetate) injection for the treatment of relapsing forms of multiple sclerosis and is available as a 20mg daily injection or as a 40mg three times weekly injection, and Azilect® (rasagiline) tablets which is for the treatment of the symptoms of Parkinson’s disease.
Multiple sclerosis (MS) is the most common cause of neurological disability in young adults and affects more than 2.5 million people worldwide.1 MS affects around 100,000 people in the UK.2 In the majority of patients, the disease is of the relapsing-remitting form (RRMS),3 which is manifested by relapses and slow progression of the disease that can affect the functioning of multiple systems.
Copaxone® 20mg is indicated for the treatment of relapsing forms of multiple sclerosis. Copaxone® 20mg is not indicated in primary or secondary progressive multiple sclerosis.4
Copaxone® 20mg is supported by a comprehensive patient support programme.
Copaxone® 40mg three times weekly is indicated for the treatment of relapsing forms of multiple sclerosis. It is not indicated for primary or secondary progressive multiple sclerosis.5
Copaxone 40mg also has a comparable safety profile to Copaxone 20mg.6
Copaxone 40mg has a lower incidence of injection site reactions compared to Copaxone 20mg6
For prescribing information please click here
Copaxone® 40mg is supported by a comprehensive patient support programme.
An estimated 10 million people worldwide are living with Parkinson's disease.7 The number of people diagnosed with Parkinson's in the UK is about 145,000. That's around 1 adult in every 350.8 There's currently no cure, but medicines and treatments are available to manage many of the symptoms.
Our Joint Working projects help the NHS and healthcare professionals deliver improved patient outcomes. Our Joint Working projects are available on our Joint Working pages.
To discuss potential Joint Working opportunities with Teva within CNS you can contact us and a representative from Teva will be in touch.
 https://www.mstrust.org.uk/a-z/prevalence-and-incidence-multiple-sclerosis [accessed 17.04.18].
 http://www.mssociety.org.uk/what-is-ms [accessed 17.04.18].
 https://www.nice.org.uk/guidance/cg186/chapter/introduction [accessed 17.04.18].
 Copaxone® (glatiramer acetate) 20mg Summary of Product Characteristics.
 Copaxone® (glatiramer acetate) 40mg Summary of Product Characteristics.
 Khan O et al. Ann Neurol 2013: 73; 705–713.
 http://parkinson.org/Understanding-Parkinsons/Causes-and-Statistics [accessed 17.04.18].
 https://www.parkinsons.org.uk/information-and-support/what-parkinsons [accessed 17.04.18].
 Azilect® (rasagiline) Summary of Product Characteristics.